Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Pfizer
M.D. Anderson Cancer Center
University of Florida
Essen Biotech
Essen Biotech
Azienda Ospedaliero-Universitaria di Parma
Miltenyi Biomedicine GmbH
Cancer Research UK
Cancer Research UK
UNC Lineberger Comprehensive Cancer Center
Duke University
National Cancer Institute (NCI)
BerGenBio ASA
Stanford University
National Cancer Institute (NCI)
Vector Vitale LLC
Cedars-Sinai Medical Center
Stanford University
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
NovalGen Ltd.
Bristol-Myers Squibb
Scripps Health
Fore Biotherapeutics
Celgene
Shenzhen BinDeBio Ltd.
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
Celldex Therapeutics
Michigan State University
Novartis
Hoffmann-La Roche
Novartis
M.D. Anderson Cancer Center
University of Washington
Rutgers, The State University of New Jersey
Eastern Cooperative Oncology Group
INSYS Therapeutics Inc
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Novartis
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)